Kraig Biocraft Laboratories Increases R&D Capacity, as Project Atlas Breakthroughs Creating New Spider Silk Transgenics
MWN-AI** Summary
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), a leader in spider silk technology, has announced a substantial upgrade to its research and development capabilities as part of its ambitious Project Atlas initiative. This expansion includes the onboarding of new scientific personnel and the introduction of advanced equipment, effectively tripling the throughput of its screening processes. This enhancement enables the team to keep pace with the burgeoning creation of new transgenics focused on developing advanced biomaterials for industrial and defense applications.
Project Atlas is the company's next-generation recombinant spider silk program, and it has generated a remarkable number of transgenics and potential candidates for new production materials. The recent upgrades streamline the evaluation of these materials and provide deeper analytical insights into the expression levels of spider silk proteins, allowing the team to efficiently identify and advance the most promising genetic constructs into production.
CEO Kim Thompson emphasized the importance of this investment, stating that it further solidifies Kraig Labs' leadership position in advanced biomaterials and enhances their competitive edge. The company has also bolstered its analytical testing capabilities, which are crucial for isolating high-performing transgenic lines amid a rapidly evolving research landscape.
Dr. Zhang, the Chief Scientist, noted that the expansion of testing infrastructure dramatically increases the capacity for analyzing multiple transgenic lines simultaneously. This increased screening power is essential for progressing swiftly in the field of biomaterials.
The recent advancements have garnered significant attention, including a feature in the March 2026 issue of National Geographic. Kraig Labs continues to solidify its reputation as a pioneering entity in the spider silk industry and remains committed to leveraging its innovative capabilities for future breakthroughs. For more information about Kraig Biocraft Laboratories, visit their website at www.kraiglabs.com.
MWN-AI** Analysis
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) has made a notable stride in its endeavor to dominate the spider silk biomaterials market by expanding its research and development (R&D) capacity. The recent announcement regarding Project Atlas reflects a proactive approach to capitalize on the rapid advancements in transgenic spider silk production. Market participants should closely analyze these developments, as they may significantly impact KBLB's growth trajectory and overall market valuation.
The expansion of Kraig Labs' laboratory facilities, coupled with enhanced screening capacity and new advanced equipment, increases throughput and accelerates the evaluation of newly created transgenic lines. By tripling its testing capabilities, the company is now well-positioned to expedite the R&D process, potentially reducing time-to-market for new products. Such improvements are crucial in a rapidly evolving sector where innovation can quickly dictate competitive advantage.
Moreover, the automation of testing workflows not only enhances efficiency but also allows for a deeper analysis of the genetic constructs involved. This capability can lead to the isolation of high-performing transgenics, ultimately advancing them into production more swiftly. The response from leadership, including CEO Kim Thompson and Chief Scientist Dr. Zhang, indicates a sustained commitment to innovation—vital for maintaining a competitive edge in advanced biomaterials.
Investors should view this strategic R&D investment as a strong signal of the company’s growth potential. Given the heightened visibility of Kraig Labs through notable features in media, such as National Geographic, the company is likely to gain increasing attention from investors and industry stakeholders alike.
It is important to remain cognizant of risks tied to biotech progress and market fluctuations, but the advancements under Project Atlas suggest a promising outlook for Kraig Biocraft Laboratories. As R&D efforts bear fruit, the potential for significant commercial applications in industrial and defense sectors could yield substantial returns for early investors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ANN ARBOR, Mich., March 23, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a significant expansion of its research and development capacity designed to keep pace with rapid progress of its advanced materials initiative, Project Atlas.
The Company has expanded its laboratory capabilities, onboarding new scientific personnel and the deployment of new advanced equipment. These improvements have roughly tripled screening throughput, allowing the R&D team to keep up with the rapid development of new transgenics.
Kraig Labs implemented these upgrades in direct response to the rapid technical progress made under Project Atlas. Atlas is the Company's next-generation recombinant spider silk program focused on creating advanced biomaterials with potential industrial and defense applications.
The recently commissioned equipment streamlines the screening of newly created transgenic lines and the analysis of their resulting spider silk expression levels. Project Atlas is now generating significant numbers of transgenics and potential candidates for new production materials. This expanded screening capacity was needed to keep pace with the rate of new transgenic creation, which is now at the highest levels in the Company's history. By automating portions of the testing workflow, Kraig Labs can now rapidly process and evaluate significantly more samples, quickly identifying new, exciting transgenics.
In addition to the increased screening capacity, Kraig Labs also strengthened its analytical testing capabilities. These tools provide deeper insight into the expression levels and functional impact of each engineered transgenic line. This enhanced visibility allows the research team to identify the most promising genetic designs and prioritize them for advancement into the Company's production pipeline.
"With the pace of discovery we are seeing in Project Atlas, it became clear that we needed to expand our screening and analysis capacity to keep up with the speed of innovation," said Kim Thompson, Founder and CEO of Kraig Labs. "This investment in staff and technology further strengthens our position as a leader in advanced biomaterials. We believe we have a wide lead on our competitors, and it is the goal of this investment to expand that lead further."
Dr. Zhang, the Company's Chief Scientist, emphasized the impact these upgrades will have on the research pipeline.
"Project Atlas involves the creation and evaluation of numerous complex genetic constructs designed to work together to produce highly specialized silk proteins," said Dr. Zhang. "The expansion of our testing infrastructure dramatically increases our testing capacity to match the increased pace of transgenic creation. We can now analyze many more transgenic lines in parallel and better quantify how each genetic insert is performing. This level of screening power is essential for isolating the highest-performing lines and rapidly advancing them into production."
By significantly increasing screening capacity and analytical insight, Kraig Labs expects to shorten development timelines and improve its ability to identify breakthrough material candidates.
The Company leadership in bioengineering was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of its work scaling spider silk production.
Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.
You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about recent Kraig Labs advancements, please watch the Company's investor updates at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/069703da-8094-422d-9874-249b0810916a
FAQ**
What specific advancements in spider silk technology is Kraig Biocraft Labs Inc KBLB targeting through its Project Atlas initiative, and how do these advancements compare to competitors in the biotechnology field?
How has the expansion of laboratory capabilities at Kraig Biocraft Labs Inc KBLB specifically impacted the development timelines for new transgenic lines and production materials?
Can Kraig Biocraft Labs Inc KBLB provide insights into the expected market demand for the advanced biomaterials being developed under Project Atlas, particularly in industrial and defense applications?
What measures are being implemented by Kraig Biocraft Labs Inc KBLB to mitigate the risks and uncertainties associated with its forward-looking statements about the company's growth and technological advancements?
**MWN-AI FAQ is based on asking OpenAI questions about Kraig Biocraft Labs Inc (OTC: KBLB).
NASDAQ: KBLB
KBLB Trading
-1.71% G/L:
$0.115 Last:
646,392 Volume:
$0.1106 Open:
